Reply to Olle et al. - Takeaways - MDSpire

Reply to Olle et al.

  • By

  • Brendan J Kelly

  • Jennie H Kwon

  • Michael H Woodworth

  • November 19, 2024

  • 0 min

Share

  • 1

    The authors express gratitude to Olle et al for clarifying terminology in microbiome-based therapeutics.

  • 2

    Clear terminology is essential for clinicians to differentiate between fecal microbiota products and live biotherapeutic products.

  • 3

    The field of microbiome-based therapeutics is rapidly evolving, necessitating precise definitions.

  • 4

    Fecal microbiota products and live biotherapeutic products may improve treatment for Clostridioides difficile infections.

  • 5

    The authors believe these therapies will benefit both patients and researchers studying their mechanisms.

Original Source(s)

Reply to Olle et al.

  • by Brendan J Kelly, Jennie H Kwon, Michael H Woodworth

  • November 19, 2024

Related Content

Caries May May Signal Oral Antibiotic Resistance

Study found species-specific differences in biofilm -forming capacity and antimicrobial susceptibility among supragingival bacterial isolates from patients with active dental caries.

The role of the complement system in gastrointestinal-related diseases

Hidden Gut Factor in Liver Disease

Healthy microbiome linked to reduced liver injury from Vibrio infection

  • May 8, 2026

  • 3 min